Results of esketamine administration in a Greek population; A case series.
Psychiatrike = Psychiatriki October 8, 2024 Petros Fotiadis, Eleni Tsalkitzi, Dimos Dimellis et al.
Esketamine is a non-selective, competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor in the brain. Through NMDA receptor antagonism, esketamine causes a transient increase in glutamate release, leading to increases in neurotrophic signaling and restoration of synaptic function in brain regions involved in mood regulation and emotional behavior. Several randomized clinical trials...